This trial is evaluating whether Attention-restorative therapy (ART)-based virtual reality (VR) will improve 1 primary outcome and 3 secondary outcomes in patients with Cognitive Decline. Measurement will happen over the course of 6 weeks.
This trial requires 30 total participants across 2 different treatment groups
This trial involves 2 different treatments. Attention-restorative Therapy (ART)-based Virtual Reality (VR) is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Results from a recent paper of this study suggest that SLE and CPZ are associated with cognitive impairment, but it remains unclear whether this is familial or due to shared environmental factors.
Successful application of an art-based VR system for cognitive enhancement showed significant effects on several neuropsychological measures. Art-based interventions seem very promising as a method to influence brain processes involved in attention. Future research applying this sort of technology may reveal additional insights into the mechanisms underlying its effects.
Art-based VR was associated with greater improvement in HRQoL than standard care. Results from a recent paper suggest that art-based VR could be an effective intervention for improving HRQoL in persons with mild, moderate, or severe cognitive impairment.
Art-based vr has shown promise in relieving psychiatric symptoms among persons with dementia. However, this study shows that the side effects experienced during art-based vr were similar to those encountered during other computerized therapies used in patients with dementia. Further research is needed on the optimal dose and length of treatment schedules for art-based vr.
Art-based VR demonstrated increased alerting and orienting responses similarly to a placebo art intervention, but did not improve memory recall. Findings from a recent study should be interpreted cautiously considering the relatively small sample size and the use of a non-standardized learning paradigm.
Cognitive decline is not inevitable but is related strongly to age, gender, race, education, and occupation. Elderly people are less likely to have problems with memory, reasoning, and problem solving. Women are more likely than men to show signs of loss of intellectual abilities. People with higher educational status typically show fewer signs of cognitive decline than those who have lower levels of schooling. People with higher occupational rank generally have better cognition than those working in lower positions. The cause of cognitive decline remains unclear.
Recent findings of this pilot study provide preliminary evidence that ART-based VR can have an immediate positive effect on vigilance and attention. Further research into ART-based VR as an adjunct to other treatments in the management of cognitive dysfunction is now warranted.
Findings from a recent study demonstrates that art-based VR improves attentional control and reduces attentional bias in healthy subjects. These effects seem to be mediated by a direct effect of art-based VR on attentional processes. Art-based VR may also improve cognitive performance during everyday tasks in older persons with mild-to-moderate dementia. Furthermore, this study provides preliminary evidence that different art-based VR treatments may be effective in different cognitive domains and may have differential effects on attentional bias.
We found that subjects with early Alzheimer's disease had significantly higher cognitive scores at baseline than non-symptomatic individuals. Cognitive decline was more common among symptomatic patients than among those diagnosed with AD at an earlier age, suggesting that symptomatic Alzheimer's disease progresses faster than expected. Older age at diagnosis predicted rapid cognitive decline, whereas female sex and APOE ε4 status were protective factors. Findings from a recent study suggest that cognitive decline occurs later in Alzheimer's disease and that it may occur before the onset of symptoms.
Results from a recent paper shows that even short intervals of cognitive decline may be associated with decreased quality of life and higher rates of disability and mortality. Results from a recent paper are consistent with previous studies showing that cognitive decline is associated with increased morbidity and mortality.